Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBIT Margin: 2020-2023

Historic EBIT Margin for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -228.43%.

  • Candel Therapeutics' EBIT Margin rose 2590383.00% to -228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was -1,479.42%, marking a year-over-year increase of 2652138.00%. This contributed to the annual value of -1,596.70% for FY2024, which is 11728.00% down from last year.
  • Per Candel Therapeutics' latest filing, its EBIT Margin stood at -228.43% for Q4 2023, which was down 117.25% from 1,324.51% recorded in Q3 2023.
  • Over the past 5 years, Candel Therapeutics' EBIT Margin peaked at 1,581.77% during Q1 2023, and registered a low of -28,987.10% during Q1 2022.
  • Over the past 3 years, Candel Therapeutics' median EBIT Margin value was -21,033.87% (recorded in 2021), while the average stood at -15,902.36%.
  • Per our database at Business Quant, Candel Therapeutics' EBIT Margin crashed by 1,703,226bps in 2021 and then spiked by 3,056,887bps in 2023.
  • Candel Therapeutics' EBIT Margin (Quarterly) stood at -19,758.06% in 2020, then crashed by 520,968bps to -24,967.74% in 2021, then tumbled by 116,452bps to -26,132.26% in 2022, then soared by 2,590,383bps to -228.43% in 2023.
  • Its EBIT Margin stands at -228.43% for Q4 2023, versus 1,324.51% for Q3 2023 and 1,487.42% for Q2 2023.